[1] Svendsen T, Brodtkorb E, Linge HL, Burns ML, Johannessen SI, Nakken KO, Lossius MI, Landmark CJ. Efficacy, tolerability and pharmacokinetic variability of brivaracetam in adults with difficult-to-treat epilepsy[J]. Epilepsy Res, 2022, 183:106946. [2] Pazarlar BA, Madsen CA, Oyar EÖ, Eğilmez CB, Mikkelsen JD. Temporal and spatial changes in synaptic vesicle glycoprotein 2A (SV2A) under kainic acid induced epileptogenesis:an autoradiographic study[J]. Epilepsy Res, 2022, 183:106926. [3] Landazuri PX, Ulloa CM. The challenges of continued antiseizure medicine trials[J]. Epilepsia, 2020, 61:2613-2614. [4] Millichap JJ, Harden CL, Dlugos DJ, French JA, Butterfield NN, Grayson C, Aycardi E, Pimstone SN. Capturing seizures in clinical trials of antiseizure medications for KCNQ2-DEE[J]. Epilepsia Open, 2021, 6:38-44. [5] Campbell C, McCormack M, Patel S, Stapleton C, Bobbili D, Krause R, Depondt C, Sills GJ, Koeleman BP, Striano P, Zara F, Sander JW, Lerche H, Kunz WS, Stefansson K, Stefansson H, Doherty CP, Heinzen EL, Scheffer IE, Goldstein DB, O'Brien T, Cotter D, Berkovic SF, Sisodiya SM, Delanty N, Cavalleri GL; EpiPGX Consortium. A pharmacogenomic assessment of psychiatric adverse drug reactions to levetiracetam[J]. Epilepsia, 2022, 63:1563-1570. [6] Brigo F, Jones K, Eltze C, Matricardi S. Anti-seizure medications for Lennox-Gastaut syndrome[J]. Cochrane Database Syst Rev, 2021, 4:CD003277. [7] Specchio N, Wirrell EC, Scheffer IE, Nabbout R, Riney K, Samia P, Guerreiro M, Gwer S, Zuberi SM, Wilmshurst JM, Yozawitz E, Pressler R, Hirsch E, Wiebe S, Cross HJ, Perucca E, Moshé SL, Tinuper P, Auvin S. International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood:position paper by the ILAE Task Force on Nosology and Definitions[J]. Epilepsia, 2022, 63:1398-1442. [8] Zuberi SM, Wirrell E, Yozawitz E, Wilmshurst JM, Specchio N, Riney K, Pressler R, Auvin S, Samia P, Hirsch E, Galicchio S, Triki C, Snead OC, Wiebe S, Cross JH, Tinuper P, Scheffer IE, Perucca E, Moshé SL, Nabbout R. ILAE classification and definition of epilepsy syndromes with onset in neonates and infants:position statement by the ILAE Task Force on Nosology and Definitions[J]. Epilepsia, 2022, 63:1349-1397. [9] Riney K, Bogacz A, Somerville E, Hirsch E, Nabbout R, Scheffer IE, Zuberi SM, Alsaadi T, Jain S, French J, Specchio N, Trinka E, Wiebe S, Auvin S, Cabral-Lim L, Naidoo A, Perucca E, Moshé SL, Wirrell EC, Tinuper P. International League Against Epilepsy classification and definition of epilepsy syndromes with onset at a variable age:position statement by the ILAE Task Force on Nosology and Definitions[J]. Epilepsia, 2022, 63:1443-1474. [10] Hirsch E, French J, Scheffer IE, Bogacz A, Alsaadi T, Sperling MR, Abdulla F, Zuberi SM, Trinka E, Specchio N, Somerville E, Samia P, Riney K, Nabbout R, Jain S, Wilmshurst JM, Auvin S, Wiebe S, Perucca E, Moshé SL, Tinuper P, Wirrell EC. ILAE definition of the Idiopathic Generalized Epilepsy Syndromes:position statement by the ILAE Task Force on Nosology and Definitions[J]. Epilepsia, 2022, 63:1475-1499. [11] Wirrell EC, Nabbout R, Scheffer IE, Alsaadi T, Bogacz A, French JA, Hirsch E, Jain S, Kaneko S, Riney K, Samia P, Snead OC, Somerville E, Specchio N, Trinka E, Zuberi SM, Balestrini S, Wiebe S, Cross JH, Perucca E, Moshé SL, Tinuper P. Methodology for classification and definition of epilepsy syndromes with list of syndromes:report of the ILAE Task Force on Nosology and Definitions[J]. Epilepsia, 2022, 63:1333-1348. [12] Chen YM, Li SC. Epilepsy, status epilepticus, and refractory status epilepticus[M]//Wang XF, Li SC. Refractory status epilepticus. Singapore:Springer, 2017:1-42. [13] Wirrell E, Tinuper P, Perucca E, Moshé SL. Introduction to the epilepsy syndrome papers[J]. Epilepsia, 2022, 63:1330-1332. [14] The International League Against Epilepsy[EB/OL].[2022-07-05]. http://www.ilae.org. [15] Xia X, Vishwanath M, Zhang J, Sarafan S, Trigo Torres RS, Le T, Lau MPH, Nguyen AH, Cao H. Microelectrode array membranes to simultaneously assess cardiac and neurological signals of xenopus laevis under chemical exposures and environmental changes[J]. Biosens Bioelectron, 2022, 210:114292. [16] Wang XF, Li F, Pan SY. Multi-modal EEG monitoring of severely neurologicall Ⅲ patients[M]. Singapore:Springer, 2022. [17] Flink R, Pedersen B, Guekht AB, Malmgren K, Michelucci R, Neville B, Pinto F, Stephani U, Ozkara C; Commission of European Affairs of the International League Against Epilepsy:Subcommission on European Guidelines. Guidelines for the use of EEG methodology in the diagnosis of epilepsy. International League Against Epilepsy:commission report[J]. Acta Neurol Scand, 2002, 106:1-7. [18] Beniczky S. Report on the availability and standard of EEG investigations across centres in EpiCARE[EB/OL].[2022-07-05].https://www.epilepsyallianceeurope.org. [19] Koutroumanidis M, Arzimanoglou A, Caraballo R, Goyal S, Kaminska A, Laoprasert P, Oguni H, Rubboli G, Tatum W, Thomas P, Trinka E, Vignatelli L, Moshé SL. The role of EEG in the diagnosis and classification of the epilepsy syndromes:a tool for clinical practice by the ILAE Neurophysiology Task Force (Part 1)[J]. Epileptic Disord, 2017, 19:233-298. [20] Koutroumanidis M, Arzimanoglou A, Caraballo R, Goyal S, Kaminska A, Laoprasert P, Oguni H, Rubboli G, Tatum W, Thomas P, Trinka E, Vignatelli L, Moshé SL. The role of EEG in the diagnosis and classification of the epilepsy syndromes:a tool for clinical practice by the ILAE Neurophysiology Task Force (Part 2)[J]. Epileptic Disord, 2017, 19:385-437. [21] Monsson OS, Roberg LE, Gesche J, Beier CP, Krøigård T. Salzburg consensus criteria are associated with long-term outcome after non-convulsive status epilepticus[J]. Seizure, 2022, 99:28-35. [22] Menon D, Marasakatla S, Holla VV, Kamble N, M N, Pal PK. Fever related super-refractory status epilepticus:an adulthood presentation of a novel POLG variant:a case report[J]. Seizure, 2022, 99:24-26. [23] Fang YT, Lee TL, Tu YH, Lin SH, Chien ME, Huang CW, Hsu KS, Wu YJ. Factors associated with mortality in patients with super-refractory status epilepticus[J]. Sci Rep, 2022, 12:9670. [24] Lu M, Faure M, Bergamasco A, Spalding W, Benitez A, Moride Y, Fournier M. Epidemiology of status epilepticus in the United States:a systematic review[J]. Epilepsy Behav, 2020, 112:107459. [25] Vossler DG, Bainbridge JL, Boggs JG, Novotny EJ, Loddenkemper T, Faught E, Amengual-Gual M, Fischer SN, Gloss DS, Olson DM, Towne AR, Naritoku D, Welty TE. Treatment of refractory convulsive status epilepticus:a comprehensive review by the American Epilepsy Society Treatments Committee[J]. Epilepsy Curr, 2020, 20:245-264. [26] Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, Shorvon S, Lowenstein DH. A definition and classification of status epilepticus:report of the ILAE Task Force on Classification of Status Epilepticusρ[J]. Epilepsia, 2015, 56:1515-1523. [27] GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016:a systematic analysis for the Global Burden of Disease Study 2016[J]. Lancet Neurol, 2019, 18:459-480. [28] Drug Therapy Committee, Chinese Association Against Epilepsy. Expert consensus on terminating status epilepticus seizures[DB/OL]. Beijing:Jie Fang Jun Yi Xue Za Zhi, 2022[2022-07-05]. https://kns.cnki.net/kcms/detail/11.1056.R.20220509.1022.002.html.[中国抗癫痫协会药物治疗委员会. 终止癫痫持续状态发作的专家共识[DB/OL]. 北京:解放军医学杂志, 2022[2022-07-05]. https://kns.cnki.net/kcms/detail/11.1056.R.20220509.1022.002.html.] |